Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has reached a pivotal moment by initiating the first patient treatment in a Phase 1 clinical trial for RAD 204, a novel PD-L1 nanobody aimed at treating Non-Small Cell Lung Cancer (NSCLC). The trial, conducted across several Australian hospitals, focuses on the safety and potential efficacy of RAD 204 in individuals with advanced NSCLC, addressing a significant need for more effective second-line treatments. This marks a key advancement for Radiopharm as it continues to develop its portfolio of cutting-edge oncology radiotherapeutics.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
